

Review

Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers

Ravi Bharadwaj ^{1,*}, Swati Jaiswal ^{1,*}, Erandi E. Velarde de la Cruz ² and Ritesh P. Thakare ²

¹ Department of Infectious Diseases, UMass Chan Medical School, Worcester, MA 01605, USA

² Department of Molecular Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA; erandi.velardedelacruz@umassmed.edu (E.E.V.d.l.C.); ritesh23thakare@gmail.com (R.P.T.)

* Correspondence: ravi.bharadwaj@umassmed.edu (R.B.); swati.jaiswal@umassmed.edu (S.J.)

† These authors contributed equally to this work.

Abstract: Solute carrier (SLC) transporters constitute a vast superfamily of transmembrane proteins tasked with regulating the transport of various substances such as metabolites, nutrients, ions, and drugs across cellular membranes. SLC transporters exhibit coordinated expression patterns across normal tissues, suggesting a tightly regulated regulatory network governing normal cellular functions. These transporters are crucial for the transport of various metabolites, including carbohydrates, proteins, lipids, and nucleic acids. However, during tumor development, metabolic changes drive an increased demand for energy and nutrients. Consequently, tumor cells alter the expression of SLC transporters to meet their heightened nutrient requirements. Targeting SLCs through inhibition or activation presents a promising therapeutic approach in cancer treatment. Certain SLCs also serve as intriguing chemo-sensitizing targets, as modulating their activity can potentially alter the response to chemotherapy. This review underscores the significance of various SLCs in tumor progression and underscores their potential as both direct and indirect targets for cancer therapy.

Keywords: SLC; transporter; colon cancer; pancreatic cancer; liver cancer; lung cancer



Citation: Bharadwaj, R.; Jaiswal, S.; Velarde de la Cruz, E.E.; Thakare, R.P. Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers. *Diseases* **2024**, *12*, 63. <https://doi.org/10.3390/diseases12030063>

Academic Editor: Antonella D'Anneo

Received: 16 February 2024

Revised: 12 March 2024

Accepted: 20 March 2024

Published: 21 March 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Transporters are specialized proteins that facilitate the movement of ions, peptides, small molecules, lipids, and macromolecules across biological membranes. These proteins play crucial roles in controlling nutrient levels, eliminating waste from cells, regulating cell volume, and maintaining cellular energy levels. For transporting a variety of compounds, specialized transporters have been classified into multiple types. However, the two major superfamilies of transporters are ABC transporters and solute carrier transporters, in addition to other transporter families [1,2]. ABC transporters utilize the energy from ATP hydrolysis and function as efflux transporters, whereas SLC transporters are primarily involved in the transporting of small molecules and ions from cells [3]. The present review provides an introductory overview of the SLC superfamily of transporter proteins and their crucial roles within human cells. The solute carrier family encompasses a diverse array of transporters that facilitate secondary active transport and facilitative diffusion mechanisms. These transporters are ubiquitously distributed across cellular compartments, spanning from the plasma membrane to the membranes of virtually every organelle. The expansive SLC superfamily comprises 65 families encompassing 458 transporters that facilitate the movement of diverse substances across cell membranes. These substances include amino acids, sugars, drugs, ions, and vitamins [4]. SLC transporters operate through secondary active transport or facilitative diffusion mechanisms, distinct from active transporters that directly utilize the energy from ATP hydrolysis. Within the SLC superfamily, transporters may function as symporters or antiporters, utilizing the electrochemical gradient of one substrate (typically ions) to provide the energy required for the transport of another substrate in an energetically unfavorable direction [5]. The proteins of the SLC superfamily

have a variety of three-dimensional structures; not all but most SLC family members share some common features. According to the hydrophobicity plot, SLC proteins are predicted to contain 1 to 16 transmembrane (TM) domains. However, 83% of SLC proteins consist of 7 to 12 transmembrane domains [6,7]. So far, all the known structures of SLC proteins have been shown to have a unique feature: pseudosymmetry within their TM domains [8]. SLC proteins are classified based on various structural features.

Among SLC proteins, two common structural folds are observed: the major facilitator superfamily (MFS) fold and the leucine transporter (LeuT-like fold). The MFS fold typically consists of two pseudo-repeats, each containing six transmembrane helices linked by a cytoplasmic loop. In contrast, the LeuT-like fold comprises two sets of five transmembrane helices, each featuring a bundle and scaffold domain. SLC proteins with the MFS fold utilize a rocker and switch mechanism, while those with the LeuT fold employ a rocking-bundle approach [8]. Additionally, some SLC proteins utilize a third mechanism known as the “elevator” mechanism [9,10]. In both the rocker-switch and the rocking-bundle models, substrate binding occurs at a binding site, initiating a shift in the transmembrane domains around the substrate. This exposes the binding site to the opposite side of the membrane, facilitating substrate release. Conversely, the elevator mechanism involves two distinct domains: a scaffold domain and a transport domain, each serving specific functions. In this mechanism, the transport domain binds the substrate and undergoes rigid body movement to translocate across the membrane, ultimately releasing the substrate [10]. In a recent article by Puris et al. and Lin et al. [11,12], the therapeutic potential of SLC transporters in cancer was explored. It was posited that the expression of SLCs is diminished in cancerous cells, potentially leading to compromised drug delivery [12], although this phenomenon remains relatively understudied. The present review seeks to consolidate existing knowledge regarding SLC transporter expression in various cancers compared to healthy tissues, as well as ongoing research endeavors aimed at elucidating the role of SLCs in cancer progression. Furthermore, recent advancements in strategies targeting SLC transporters, such as the development of transporter-utilizing prodrugs, and the modulation of SLC transporter expression in cancer cells, are discussed.

2. SLC Transporters in Cancer

Many studies have emphasized the crucial involvement of the SLC superfamily in various aspects of tumorigenesis, including invasion, proliferation, metastasis, apoptosis, chemotherapy resistance, and other cancer-related processes. SLC transporters facilitate the entry of diverse metabolically significant substrates into cells, which is essential for human physiology. These processes include glucose absorption, uptake of water-soluble vitamins crucial for vital functions, transportation of metal ions, amino acid intake in the intestine, and reabsorption of neurotransmitters into presynaptic neurons [11]. Tumorigenesis, a complex process, orchestrates the conversion of normal cells into highly malignant derivatives [12,13]. In certain cases, cancer cells may increase the expression of SLC transporters to fulfill nutritional needs, which gives them an advantage over normal cells when nutrients are scarce. For example, the phenomenon known as the Warburg effect comprises cancer cells increasing the uptake of glucose and aerobic glycolysis to meet the highly metabolically active state [14]. Conversely, certain SLC transporters can facilitate the delivery of specific drugs to cancer cells, presenting novel avenues to enhance chemotherapy sensitivity and counter drug resistance [15]. Notably, the SLC16 transporter family (figure not shown), also referred to as monocarboxylic acid transporters (MCTs), plays a pivotal role in cancer metabolism [15,16]. This family, comprising MCT1-4 (SLC16A1, SLC16A7, SLC16A8, SLC16A3), primarily mediates the transport of monocarboxylic acids, such as lactic acid, thereby regulating cellular pH and overall homeostasis [15,17]. In cancer cells, elevated glycolysis levels lead to upregulated expression of MCT1-4. Moreover, SLC16A1, SLC16A3, and SLC16A13 have emerged as promising biomarkers for prognostication in pancreatic cancer [18]. MCT5 (SLC16A4), expressed in the basolateral membrane of the colon, likely participates in nutrient absorption [19]. Lin et al. demonstrated upregulated

MCT5 expression in colon cancer, underscoring its potential relevance in this context [20]. Moreover, MCT1 (SLC16A1) has been implicated in breast cancer, where its overexpression is frequently observed [21]. By selectively targeting MCT1, researchers have found that the disruption of pyruvate export significantly impacts the metabolic pathways essential for cancer cell proliferation. This approach effectively starves the cancer cells, leading to impaired growth and proliferation. These findings underscore the potential of MCT1 inhibition as a therapeutic strategy for targeting glycolytic breast cancer cells and highlight the importance of understanding the specific metabolic dependencies of cancer cells for developing targeted therapies [22]. The subsequent sections provide summaries of select SLC transporters implicated in various aspects of pancreatic tumor biology, elucidating their roles. We have delineated the functions of each differentially expressed SLC transporter in cancerous cells and their corresponding inhibitors in Table 1 and Figures 1–6.




Figure 1. SLC transporters in pancreatic cancer. SLC7A5, SLC1A5, and SLC7A11 help with amino acid transport and play a role in chemoresistance and metastasis by activating the mTOR pathway. SLC39A4 activates the CREB transcription factor and plays a role in metastasis, invasion, and cell proliferation together with SLC39A6 and SLC39A3. SLC4A7 transports sodium bicarbonate and helps with tumor proliferation. SLC22A5 helps with tumor progression, while SLC5A8 and SLC41A1 play a role in tumor suppression. (Stars show the inhibitors of specific transporters and the substrates are in the colored text.) The image was created in BioRender.




Figure 2. SLC transporters in breast cancer. SLC04A1, SLC04C1, and SLC01A2 transport steroid hormones (E3) and play a role in cell proliferation and tumor growth. SLC01B1 and SLC01B3 promote chemoresistance, as they transport several chemotherapy drugs. SLC02A1 and SLC02A4 transport progesterone (PG) and promote angiogenesis and proliferation. SLC22A5 helps with cancer development (see text). The image was created in BioRender.




Figure 3. SLC transporters in leukemia. The SLC38A1, SLC1A5, and SLC2 families promote metastasis, invasion, and cell proliferation (see text). Other transporters like SLC22A1, SLC29A1, SLC19A1, and SLC7A7 play important roles in transporting anti-cancer drugs. (Stars show the inhibitors of specific transporters and the substrates are in the colored text.) The image was created in BioRender.




Figure 4. SLC transporters in colon cancer. SLC7A5, SLC1A5, and SLC39A4 play a role in chemoresistance by activating the CREB transcription factor. SLC39A7 plays a role in metastasis. (Stars show the inhibitors of specific transporters and the substrates are in the colored text.) The image was created in BioRender.




Figure 5. SLC transporters in lung cancer. SLC7A5, SLC1A5, SLC39A3, SLC39A4, and SLC39A7 promote chemoresistance as in pancreatic cancer. SLC22A18 plays a role in metastasis. SLC18A1, SLC29A3, and SLC38A3 transport amino acids and monoamines (see text). SLC22A16 transports doxorubicin (DOX). (Stars show the inhibitors of specific transporters and the substrates are in the colored text.) The image was created in BioRender.




Figure 6. SLC transporters in liver cancer. SLC2A1 and SLC2A2 transport glucose and fructose, respectively, and promote metastasis. SLC26A6 plays a role in tumorigenesis. SLC39A6, SLC13A5, SLC02A1, and SLC02B1 are important in cell proliferation. (Stars show the inhibitors of specific transporters and the substrates are in the colored text.) The image was created in BioRender.

2.1. Pancreatic Cancer

Pancreatic cancer ranks as the seventh leading cause of cancer-related deaths worldwide, with approximately 432,242 new deaths annually according to GLOBOCAN 2018 [15,16]. Despite its relatively low incidence, pancreatic cancer remains highly lethal, boasting a dismal five-year overall survival rate of approximately 8%, solidifying its place as a significant contributor to global cancer mortality [18]. Within pancreatic cancer, ten SLC transporters have emerged as key players in chemoresistance, tumor proliferation, and, notably, tumor suppression (Figure 1).

One of these transporters, SLC1A5, encodes the alanine–serine–cysteine transporter 2 (ASCT2) protein responsible for transporting neutral amino acids in a sodium ion-dependent manner. SLC1A5 is predominantly expressed in mitochondria, facilitating the transport of glutamine and other neutral amino acids into these organelles [19,20]. Elevated expression of SLC1A5 has been observed in surgically extracted tumor samples compared to adjacent tissues or benign pancreatic lesions, indicating its potential role in pancreatic tumor progression. Knockdown experiments targeting SLC1A5 expression have resulted in a drastic reduction in tumor cell proliferation, further underscoring its significance in pancreatic cancer pathogenesis [19].

Similarly, SLC4A7, known as a sodium and bicarbonate ion cotransporter (NBC3), plays a pivotal role in regulating intracellular pH in pancreatic cells. Recent studies have implicated SLC4A7 in tumor growth by inducing micropinocytosis in SLC4A7 knockout Ras mutant pancreatic ductal adenocarcinoma (PDAC) cells [23].

SLC7A5, another transporter, regulates the influx of L-leucine and the efflux of L-glutamine. Its high expression has been correlated with CD147 expression, proliferation, angiogenesis, and mammalian target of rapamycin (mTOR) signaling in pancreatic cancer cells [24].

SLC7A11, a cystine/glutamate antiporter, promotes pancreatic cancer proliferation through its role in glutathione biosynthesis. Overexpression of SLC7A11 has been shown to enhance pancreatic cancer proliferation, while downregulation reverses this effect [25,26].

Members of the SLC30 and SLC39 families, which regulate zinc transportation with opposing functions, have also been implicated in pancreatic cancer. For instance, SLC39A4 exhibits significantly increased expression in pancreatic cancer tissues compared to normal tissue and has been linked to enhanced cell proliferation [27]. Similarly, SLC39A6, a downstream target of STAT3, plays a crucial role in regulating the epithelial-to-mesenchymal transition (EMT) in pancreatic cancer cells [28].

SLC5A8, a sodium-coupled monocarboxylate transporter 1 (SMCT1), transports monocarboxylates such as lactate, butyrate, pyruvate, acetate, propionate, nicotinate, and β -hydroxybutyrate. Its reduced expression and nuclear translocation have been associated with the Warburg effect in tumor cells and poor prognosis in pancreatic cancer patients [29–34].

Additionally, SLC39A3 and SLC41A1 have been reported to suppress tumor growth by downregulating Ras-responsive element-binding protein 1 (RREB1) and suppressing the activation of Akt/mTOR signaling, respectively [35–37]. These findings collectively highlight the diverse roles of SLC transporters in pancreatic cancer progression and underscore their potential as therapeutic targets for this deadly disease.

2.2. Breast Cancer

Breast cancer (BC) stands as the most prevalent malignancy in females and remains a leading cause of cancer-related mortality worldwide, constituting 12% of new cases annually in the United States [38]. Although the role of ABC transports in BC has been extensively studied, recent attention has shifted towards other membrane transporters, particularly members of the SLC family, which are pivotal in transporting a diverse range of metabolites and ions across cellular membranes (Figure 2) [4]. Among these, SLCO1A2 (OATP1A2) emerges as a significant player, being expressed in various tissue types and primarily involved in transporting prostaglandins, steroid hormones/conjugates, and anticancer drugs [39]. BC cells exhibit a tenfold increase in SLCO1A2 expression compared to healthy tissue, facilitating the uptake of dehydroepiandrosterone sulfate (DHEA-S) and potentially promoting BC cell proliferation. Inhibition of SLCO1A2 activity restricts BC cell growth [40–42]. High expression of SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3) has also been observed in BC, correlating with increased uptake rates of paclitaxel and potentially influencing the deposition of clinically relevant drugs. Notably, SLCO1B3 expression inversely correlates with tumor size and is associated with a decreased risk of recurrence [43–45].

Another noteworthy SLC transporter in BC is SLCO2A1 (OATP2A1), identified as a prostaglandin transporter, which is upregulated in BC cell lines and tissues compared to normal tissue. Elevated expression of SLCO2A1 has been linked to increased intra-tumoral prostaglandins, contributing to several cancer hallmarks and supporting a cancer stem cell-like phenotype [46,47]. SLCO3A1 and SLCO4A1, widely expressed transporters, exhibit relatively high expression in BC cell lines and malignant tissues, playing essential roles in E-3-S transport and BC proliferation [48,49]. Both SLCO4A1 and SLCO4C1 facilitate the excretion of various drugs and compounds, including methotrexate, thyroid hormones, and E-3-S, with elevated expression reported in BC cell lines [49–53]. A comprehensive analysis of SLC protein expression and function in BC is crucial to elucidate their role in disease progression. Functional experiments can provide insights into the interplay between SLC transporters, nuclear receptors, and ABC transporters, potentially identifying new targets to impede BC progression to metastatic stages.

2.3. Leukemia

Leukemia, a progressive malignancy affecting blood-forming organs, is characterized by abnormal proliferation and development of leukocytes in the blood and bone marrow.

In the United States, approximately 29,000 adults and 2000 children are diagnosed with leukemia annually. Leukemia is classified into lymphocytic and myeloid types based on the involved progenitor cells [54]. Major solute carrier (SLC) proteins serve as therapeutic targets in leukemia (Table 1, Figure 3).

Table 1. List of SLC transporters expressed in different tumors, their function, and relevant inhibitors.

Cancer	Solute Carrier Transporters	Function	Inhibitors/Substrates
Pancreatic cancer	SLC1A5 (alanine–serine–cysteine transporter 2)	Transports neutral amino acid with co-transportation in a sodium ion-dependent manner	V9302 [55]
	SLC4A7 (sodium and bicarbonate ion co-transporter)	Plays a critical role in regulating the intracellular pH of pancreatic cells	S0859 [23]
	SLC7A5 (L-type amino acid transporter 1; LAT1)	Regulates the influx of L-leucine and the efflux of L-glutamine	JPH203 [56], KYT 0353 [57,58], melphalan, acivicin [11]
	SLC7A11 cystine/glutamate antiporter)	Raises glutathione biosynthesis through the uptake of cystine and the release of glutamate [22]	HG106 [11,59]
	SLC30	Involved in the efflux of zinc	-
	SLC39A3, SLC39A4, and SLC39A6	Involved in the absorption of zinc and increased cell proliferation	-
	SLC5A8 (Na ²⁺ -coupled monocarboxylate transporter 1	Co-transporters monocarboxylates such as lactate, butyrate, pyruvate, acetate, propionate, nicotinate, and β -hydroxybutyrate [29–31]	-
	SLC41A1	Suppress tumor growth [33–35]	-
	SLC22A5 (OCTN2)	Zwitterions (L-carnitine), organic cations	Etoposide, imatinib [11]
Breast Cancer	SLCO1A2 (OATP1A2)	Involved in transporting prostaglandin and steroid hormones/conjugates; estradiol-17 β -glucuronide, estrone-3-sulfate (E-3-S), dehydroepiandrosterone sulfate (DHEA-S), and anticancer drugs; and imatinib, methotrexate, paclitaxel, doxorubicin, and docetaxel [39]	Imatinib, methotrexate [11]
	SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3)	Related to drug uptake	Cisplatin, carboplatin, oxaliplatin, regorafenib, belzutifan, SN-38, etoposide, tamoxifen, nilotinib, docetaxel, imatinib, gefitinib [11], sorafenib [60]
	SLCO2A1 (OATP2A1) and SLCO2A4	Involved in prostaglandin transport	Suramin [61]
	SLCO4A1 and SLCO4C1	Promote the elimination of external medications and internal substances such as methotrexate, thyroid hormones, and E-3-S [48,49]	-
	SLC22A5 (OCTN2)	Transports zwitterions (L-carnitine), organic cations	Etoposide, imatinib [11]

Table 1. Cont.

Cancer	Solute Carrier Transporters	Function	Inhibitors/Substrates
Leukemia	SLC38A1	Transports glutamine and plays a crucial role in maintaining the homeostasis of the human body [62]	-
	SLC2 family (SLC2A5, SLC2A10, and SLC2A13)	Encodes glucose transporter (GLUT) proteins [63]	MSNBA and H22954 [64]
	SLC19A1	Transports reduced folate and found to be associated with methotrexate drug	Methotrexate, pemetrexed [11]
	SLC29A1 (ENT1)	Cellular uptake of anticancer nucleoside agents as well as physiologic nucleosides	Gemcitabine, cytarabine, 5-fluorouracil, 6-mercaptopurine [11], NBMPR [65]
	SLC22A1 (OCT1)	Transport of organic cations, i.e., nutrients, neurotransmitters, metabolites, or drugs [66]	Nintendanib [11]
	SLC1A5	Uptake of neutral amino acids, including glutamine (Gln), cysteine (Cys), serine (Ser), threonine (Thr), valine (Val), and alanine (Ala) [67,68]	V9302 [55] GPNA [69]
	SLC7A7	Transports cationic amino acids such as arginine and lysine out of the cell	-
Colon cancer	SLC19A3 (thiamine transporter 2; THTR2)	Manipulates the DNA methylation and histone deacetylation status of the nucleic acid of these cells	-
	SLC3A2	Putrescine and arginine importer	-
	SLCO4A1	Transport of various compounds, including sugars, bile salts, organic acids, metal ions, amine compounds, and estrogen, and high expression has been reported in many cancer types, including colon cancer [70,71]	-
	SLC22A3 (OCT3)	Organic cation transporter 3	Oxaliplatin [11]
	SLC35A2 and SLC29A1	Nucleoside transporter	-
	SLC1A5	Glutamine transporter	Cetuximab [72]
	SLC10A2	Associated with the progression of colorectal cancer, especially in kids [73]	-
	SLC7A2	Inducible transporter of the semi-essential amino acid L-arginine (L-Arg)	-
	SLC37A1	Involved in the sugar–phosphate exchange	-

Table 1. Cont.

Cancer	Solute Carrier Transporters	Function	Inhibitors/Substrates
Lung cancer	SLC18A1	Transports monoamines, such as norepinephrine, epinephrine, dopamine, and serotonin, and has been associated with neuropsychiatric disorders [74]	-
	SLC39A3, SLC39A4, and SLC39A7	Zn ²⁺ influx transporter, essential role in cell survival of lung adenocarcinoma	NVS-ZP7-4 [69]
	SLC1A5	Transports glutamine and regulates the cell growth and oxidative stress in non-small cell lung cancer [75]	Gamma-l-glutamyl-p-nitroanilide (GPNA) [76]
	SLC29A3	Nucleoside transporter	NBMPR [65]
	SLC7A5	Plays important role in non-small cell lung cancer [77]	JPH203 [56], KYT 0353 [58], melphalan, acivicin [11]
	SLCO2A1 (OATP2A1)	Organic anion transporter, reported to function in the progression of lung cancer	Suramin [61]
	SLC38A3	An amino acid transporter, specifically of L-glutamine, L-histidine, L-alanine, and L-asparagine	-
	SLC22A16 (OCT6)	Mediates platinum influx into cancer cells	-
	SLC22A18	Regulates cellular metabolism, cellular growth, and drug sensitivity [78]	-
	SLC22A5 (OCTN2)	Zwitterions (L-carnitine), organic cations	Etoposide, imatinib [11]
Liver cancer	SLC39A6	Significantly upregulated in liver cancer tissues compared with normal liver tissues [79]	-
	SLC26A6	Nonselective anion exchanger that transports anions such as oxalate, formate, and sulfate [80]	DIDS [81]
	SLC2A1	Glucose transporter and increased in HCC	GRg3, 1:1 CC-DG mixture [64]
	SLC2A2	Glucose transporter and decreased in HCC [82,83]	Streptozotocin [11]
	SLC13A5	A sodium-coupled citrate transporter, plays a key role in importing citrate from the circulation into liver cells [84,85]	BI01383298 [86]
	SLCO2B1 (OATP2B1)	An organic anion transporter; decreased expression in liver cancer	Etoposide, erlotinib [11]
	SLCO2A1 (OATP2A1)	Increased level of mRNA observed in hepatic tumors	Suramin [61]

Solute carrier family 38 member 1 (SLC38A1), primarily transporting glutamine, is crucial for maintaining human body homeostasis. Dysregulation of SLC38 transporters may contribute to tumor initiation and progression, with high SLC38A1 expression linked to poorer prognosis in acute myeloid leukemia (AML) and shorter overall survival [87].

Members of the SLC2 family, including SLC2A5, SLC2A10, and SLC2A13, are associated with AML prognosis. High SLC2A5 and SLC2A10 expression correlates with poor survival, while low SLC2A13 expression is linked to increased mortality [63,88].

Solute carrier family 19 member 1 (SLC19A1) transports reduced folate and is involved in methotrexate drug transportation in leukemia. Higher SLC19A1 expression predicts better overall survival [89].

Solute carrier family 29 member 1 (SLC29A1 or ENT1) facilitates cellular uptake of anticancer nucleoside agents. Elevated SLC29A1 expression disrupts 5-fluorouracil (5-FU) absorbance, impacting cancer treatment [61].

Organic cation transporter 1 (OCT1), encoded by SLC22A1, transports organic cations. Reduced OCT1 expression in AML patients correlates with higher chances of achieving complete remission and longer overall survival [60,66].

SLC1A5, a transmembrane transporter for neutral amino acids, is highly expressed in AML. Inhibition disrupts leucine influx, induces apoptosis, and impedes leukemia progression [67,68,90].

Amino acid transporter SLC7A7 influences T-cell acute lymphoblastic leukemia pathogenesis by enhancing arginine transport in cancer cells [91–94].

2.4. Colon Cancer

Colon cancer, the third most common and fourth deadliest cancer globally, claims almost 900,000 lives annually and predominates as the most prevalent gastrointestinal cancer [94]. Mika et al. demonstrated in colon cancer cell lines that altering the expression of thiamine transporter 2 (THTR2) (SLC19A3) can modulate DNA methylation and histone deacetylation, associated with thiamine deficiency in advanced colon cancer. Glutamine transporter solute carrier family 1 member 5 (SLC1A5) inhibition or downregulation in SW620/Ad300 cells reduces glutamine supply, impeding cancer cell proliferation [95]. OCT1 transporter (SLC22A1) mRNA expression increases in colon cancer cell lines and patient-derived colorectal tumor samples, proposed as a prognostic marker for colon cancer [96,97]. SLCO1B3 (OATP1B3; not shown in the figure) overexpression in HCT116 colon cancer cells inhibits apoptosis and enhances cell survival by suppressing p53 activity through SN38 [98]. Knockdown of SLC3A2, an importer of putrescine and arginine, triggers DNA replication decrease and autophagy induction in colon cancer cells [99,100]. High expression of SLCO4A1, implicated in transporting various compounds, including estrogen, in colon cancer enhances carcinogenic abilities and E1S uptake, impacting colorectal cancer prognosis [70,71,101]. High levels of nucleoside transporter SLC29A1 correlate with poor clinical response to 5-FU in colorectal tumor tissue [102], while SLC35A2 is abundantly expressed in colon cancer cells compared to non-malignant tissue. SLC22A3 expression significantly increases in colorectal cancer tissues, with its inhibition in colon cancer cell lines suppressing cancer cell proliferation, migration, and invasion and promoting apoptosis [103]. SLC5A8 transports the bacterial fermentation product butyrate, acts as a conditional tumor suppressor in colon cancer, and is linked to dietary fiber content [73]. Dysfunction in bile acid transporter ASBT (SLC10A2) is associated with colorectal cancer advancement, particularly in pediatric cases [73], and SLC7A2 deficiency exacerbates colitis and increases the risk of colitis-associated colon tumorigenesis [104]. SLC37A1 expression significantly increases in colon tumor tissues, which is associated with hematogenous metastasis and glycolipid metabolism, indicating a potential role in colon cancer progression [105]. High GLUT1 staining correlates with an increased risk of death from colon carcinoma [106].

2.5. Lung Cancer

Lung cancer ranks among the most prevalent and deadliest cancers globally, with approximately 2 million new cases and 1.76 million deaths annually [107].

SLC18A1, a vesicular monoamine transporter facilitating the transport of monoamines like norepinephrine, epinephrine, dopamine, and serotonin, has been linked to neuropsychiatric disorders. Alterations in SLC18A1 expression have been observed in lung cancer patients, and its function is speculated to complement other biomarkers under study in PD1/PD-L1 inhibition [74,108].

The SLC39A family, acting as Zn²⁺ influx transporters, has several members associated with different lung cancer forms. SLC39A3, SLC39A4, and SLC39A7 expressions are linked

to lung squamous cell carcinoma prognosis, with SLC39A7 playing a crucial role in lung adenocarcinoma (LUAD) cell survival and proliferation [109,110].

Solute carrier family A1 member 5 (SLC1A5) is primarily involved in glutamine transport, regulating cell growth and oxidative stress in non-small cell lung cancer (NSCLC). Inhibition or knockdown of SLC1A5 decreases glutamine content, reducing cell growth and viability through mTOR signaling [75,79].

SLC29A3, encoding ENT3, affects overall survival (OS) and response to gemcitabine-based chemotherapy in lung cancer patients. Elevated OCTN1 and OCTN2 mRNA levels are reported in human lung carcinoma, while LAT1 (SLC7A5) is upregulated in NSCLC [77,111–113].

SLCO2A1, an organic anion transporter, facilitates prostaglandin E2 uptake, promoting lung cancer cell invasion via the PI3K/AKT/mTOR pathway [114,115].

SLC38A3 upregulation in metastatic NSCLC cells correlates with patient prognosis, promoting metastasis through PDK1/AKT signaling activation by reducing glutamine and histidine concentrations [116].

SLC22A16 (OCT6), a high-affinity carnitine transporter, mediates platinum influx into cancer cells, and its downregulation contributes to acquired platinum resistance in lung cancer. SLC22A18 aberrant expression is observed in various cancers, including NSCLC, impacting cellular metabolism, growth, and drug sensitivity [78,113,117–119]. However, the molecular mechanisms underlying SLC22A18's roles in NSCLC remain unclear.

2.6. Liver Cancer

Liver cancer ranks among the most prevalent malignant solid tumors worldwide, standing as the fourth leading cause of cancer-related mortality and sixth in cancer incidence, with projections indicating more than one million deaths by 2030 [120]. Hepatocellular carcinoma (HCC) accounts for 70–85% of primary liver cancer cases [121]. Chronic liver diseases, including hepatitis B and C infections, non-alcoholic fatty liver disease, and alcohol abuse, are frequent precursors to liver cancer development [122–124]. Recent investigations have highlighted a significant upregulation of SLC39A6 in liver cancer tissues compared to normal liver tissues, correlating with poorer overall survival rates [125]. Solute carrier family 26 member 6 (SLC26A6) exhibits overexpression in human HCC and is associated with various cancer-related pathways [80,126]. Human organic solute carrier protein 1 (hOSCP1) variants predispose individuals to non-viral liver carcinoma [126]. Glucose transporters SLC2A1 and SLC2A2 are implicated in HCC; SLC2A1 is elevated, while SLC2A2 is decreased, correlating with clinical characteristics and prognosis [82,83,127]. SLC13A5, a sodium-coupled citrate transporter, plays a crucial role in hepatic energy homeostasis and hepatoma cell proliferation [84,85]. Organic anion-transporting polypeptides (OATPs) are upregulated in various solid tumors, including liver cancer, with SLCO2A1 (OATP2A1) elevated in HCC and liver metastases from colon cancer, while SLCO1B1 expression decreases in liver cancer, showing a reverse trend with cancer grade [128,129]. There is an increased expression of SLC46A3 reported in HCC patients' livers [12]; however, we found that it significantly expresses in the gut region and plays an important role in bacterial mucopeptide transportation [57,130].

3. Conclusions and Future Directions

Transporters play an important role in the modulation of metabolism and ion homeostasis of tumor cells, both important factors in proliferation, apoptosis, hypoxia, and migration [15]. SLC transporters represent a plethora of new therapeutic targets for rare diseases and many metabolic disorders by being amenable to targeting small molecules [11,17]. Importantly, many SLC transporters are expressed on the cell surface and therefore could be targeted by small molecules and therapeutic antibodies [15,131]. Additionally, numerous SLC transporters serve as targets for both already-approved medications and drugs currently in the developmental stage. Furthermore, extensive research is imperative to unveil potential variances in transporter expression among various cancer subtypes, partic-

ularly considering that cancers induced by mutations in oncogenes or tumor suppressor genes may exhibit substantial differences in their expression of drug transporters. Such investigations would offer insights into the regulation of transporter expression across different cancer subtypes and could provide valuable hints on selectively modulating drug transporter expression to enhance the delivery of anticancer drugs. Uncontrolled cell proliferation is a fundamental trait of cancer cells. Recent studies suggest that SLC transporters exhibit differential expression between proliferating and migrating, invasive tumor cells. Although some of these transporters may be regulated by the tumor microenvironment, much remains unknown about the relevance of distinct tumor cell subpopulations in tumor progression, dissemination, variations in transporter expression among these subpopulations, and the impact of surrounding tissue on transporter regulation. Transporters offer various avenues for exploitation in cancer treatment, including direct targeting using small molecules or antibodies to inhibit their function, or utilizing them as carriers for drugs to enhance drug efficacy. Despite recent strides in investigating SLC transporters, significant gaps persist in understanding their contribution to anticancer drug delivery and the diminished drug efficacy resulting from low expression of drug influx transporters. Nevertheless, promising innovative strategies proposed for augmenting transporter-mediated anticancer drug delivery hold the potential for overcoming transporter-mediated anticancer drug resistance and advancing the development of efficacious anticancer treatments.

Author Contributions: Writing—original draft, review, and editing—R.B. and S.J. Figure preparation—S.J. and E.E.V.d.l.C. Review and editing—E.E.V.d.l.C. and R.P.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We are thankful to the UMass Chan Medical School library for providing all the resources.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Stein, W.D.; Litman, T. *Channels, Carriers, and Pumps: An Introduction to Membrane Transport*; Elsevier: Amsterdam, The Netherlands, 2014.
2. Gautier, A.; Hinner, M.J. *Site-Specific Protein Labeling*; Springer: Berlin/Heidelberg, Germany, 2015.
3. The International Transporter Consortium. *Membrane Transporters in Drug Development*. *Nat. Rev. Drug Discov.* **2010**, *9*, 215–236.
4. Hediger, M.A.; Clémenton, B.; Burrier, R.E.; Bruford, E.A. The ABCs of Membrane Transporters in Health and Disease (SLC Series): Introduction. *Mol. Asp. Med.* **2013**, *34*, 95–107. [[CrossRef](#)]
5. Rudnick, G.; Krämer, R.; Blakely, R.D.; Murphy, D.L.; Verrey, F. The SLC6 Transporters: Perspectives on Structure, Functions, Regulation, and Models for Transporter Dysfunction. *Pflüg. Arch.-Eur. J. Physiol.* **2014**, *466*, 25–42. [[CrossRef](#)]
6. Bai, X.; Moraes, T.F.; Reithmeier, R.A. Structural Biology of Solute Carrier (SLC) Membrane Transport Proteins. *Mol. Membr. Biol.* **2017**, *34*, 1–32. [[CrossRef](#)]
7. UniProt Consortium. UniProt: A Worldwide Hub of Protein Knowledge. *Nucleic Acids Res.* **2019**, *47*, D506–D515. [[CrossRef](#)]
8. Shi, Y. Common Folds and Transport Mechanisms of Secondary Active Transporters. *Annu. Rev. Biophys.* **2013**, *42*, 51–72. [[CrossRef](#)]
9. Garib Singh, R.-A.A.; Schlessinger, A. Advances and Challenges in Rational Drug Design for SLCs. *Trends Pharmacol. Sci.* **2019**, *40*, 790–800. [[CrossRef](#)] [[PubMed](#)]
10. Drew, D.; Boudker, O. Shared Molecular Mechanisms of Membrane Transporters. *Annu. Rev. Biochem.* **2016**, *85*, 543–572. [[CrossRef](#)] [[PubMed](#)]
11. Puris, E.; Fricker, G.; Gynther, M. The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy. *Pharmaceutics* **2023**, *15*, 364. [[CrossRef](#)]
12. Zhao, Q.; Zheng, B.; Meng, S.; Xu, Y.; Guo, J.; Chen, L.J.; Xiao, J.; Zhang, W.; Tan, Z.R.; Tang, J.; et al. Increased Expression of SLC46A3 to Oppose the Progression of Hepatocellular Carcinoma and Its Effect on Sorafenib Therapy. *Biomed. Pharmacother.* **2019**, *114*, 108864. [[CrossRef](#)] [[PubMed](#)]
13. Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. *Cell* **2000**, *100*, 57–70. [[CrossRef](#)]
14. Nyquist, M.D.; Prasad, B.; Mostaghel, E.A. Harnessing Solute Carrier Transporters for Precision Oncology. *Molecules* **2017**, *22*, 539. [[CrossRef](#)]
15. Gyimesi, G.; Hediger, M.A. Transporter-Mediated Drug Delivery. *Molecules* **2023**, *28*, 1151. [[CrossRef](#)]

16. Halestrap, A.P.; Meredith, D. The SLC16 Gene Family—from Monocarboxylate Transporters (MCTs) to Aromatic Amino Acid Transporters and Beyond. *Pflug. Arch.* **2004**, *447*, 619–628. [[CrossRef](#)] [[PubMed](#)]
17. Bonglack, E.N.; Messinger, J.E.; Cable, J.M.; Ch'ng, J.; Parnell, K.M.; Reinoso-Vizcaíno, N.M.; Barry, A.P.; Russell, V.S.; Dave, S.S.; Christofk, H.R.; et al. Monocarboxylate Transporter Antagonism Reveals Metabolic Vulnerabilities of Viral-Driven Lymphomas. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2022495118. [[CrossRef](#)] [[PubMed](#)]
18. Yu, S.; Wu, Y.; Li, C.; Qu, Z.; Lou, G.; Guo, X.; Ji, J.; Li, N.; Guo, M.; Zhang, M.; et al. Comprehensive Analysis of the SLC16A Gene Family in Pancreatic Cancer Via Integrated Bioinformatics. *Sci. Rep.* **2020**, *10*, 7315. [[CrossRef](#)] [[PubMed](#)]
19. Gill, R.K.; Saksena, S.; Alrefai, W.A.; Sarwar, Z.; Goldstein, J.L.; Carroll, R.E.; Ramaswamy, K.; Dudeja, P.K. Expression and Membrane Localization of MCT Isoforms Along the Length of the Human Intestine. *Am. J. Physiol. Cell Physiol.* **2005**, *289*, C846–C852. [[CrossRef](#)]
20. Lin, W.R.; Chiang, J.M.; Lim, S.N.; Su, M.Y.; Chen, T.H.; Huang, S.W.; Chen, C.W.; Wu, R.C.; Tsai, C.L.; Lin, Y.H.; et al. Dynamic Bioenergetic Alterations in Colorectal Adenomatous Polyps and Adenocarcinomas. *EBioMedicine* **2019**, *44*, 334–345. [[CrossRef](#)]
21. Hong, C.S.; Graham, N.A.; Gu, W.; Espindola Camacho, C.; Mah, V.; Mares, E.L.; Alavi, M.; Bagryanova, L.; Krotee, P.A.L.; Gardner, B.K.; et al. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. *Cell Rep.* **2016**, *14*, 1590–1601. [[CrossRef](#)] [[PubMed](#)]
22. Benjamin, D.; Robay, D.; Hindupur, S.K.; Pohlmann, J.; Colombi, M.; El-Shemerly, M.Y.; Maira, S.M.; Moroni, C.; Lane, H.A.; Hall, M.N. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin Due to NAD⁺ Depletion in Cancer Cells. *Cell Rep.* **2018**, *25*, 3047–3058.e4. [[CrossRef](#)]
23. Ramirez, C.; Hauser, A.D.; Vucic, E.A.; Bar-Sagi, D. Plasma Membrane V-ATPase Controls Oncogenic RAS-Induced Macropinocytosis. *Nature* **2019**, *576*, 477–481. [[CrossRef](#)] [[PubMed](#)]
24. Kaira, K.; Arakawa, K.; Shimizu, K.; Oriuchi, N.; Nagamori, S.; Kanai, Y.; Oyama, T.; Takeyoshi, I. Relationship between CD147 and Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Pancreatic Cancer. *Am. J. Transl. Res.* **2015**, *7*, 356–363.
25. Koppula, P.; Zhang, Y.; Zhuang, L.; Gan, B. Amino acid Transporter SLC7A11/xCT at the Crossroads of Regulating Redox Homeostasis and Nutrient Dependency of Cancer. *Cancer Commun.* **2018**, *38*, 12. [[CrossRef](#)]
26. Zhu, J.-H.; De Mello, R.A.; Yan, Q.-L.; Wang, J.-W.; Chen, Y.; Ye, Q.-H.; Wang, Z.-J.; Tang, H.-J.; Huang, T. MiR-139-5p/SLC7A11 Inhibits the Proliferation, Invasion and Metastasis of Pancreatic Carcinoma Via PI3K/Akt Signaling Pathway. *Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.* **2020**, *1866*, 165747. [[CrossRef](#)]
27. Li, M.; Zhang, Y.; Liu, Z.; Bharadwaj, U.; Wang, H.; Wang, X.; Zhang, S.; Liuzzi, J.P.; Chang, S.-M.; Cousins, R.J. Aberrant Expression of Zinc Transporter ZIP4 (SLC39A4) Significantly Contributes to Human Pancreatic Cancer Pathogenesis and Progression. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 18636–18641. [[CrossRef](#)]
28. Unno, J.; Satoh, K.; Hirota, M.; Kanno, A.; Hamada, S.; Ito, H.; Masamune, A.; Tsukamoto, N.; Motoi, F.; Egawa, S. LIV-1 Enhances the Aggressive Phenotype through the Induction of Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma Cells. *Int. J. Oncol.* **2009**, *35*, 813–821. [[PubMed](#)]
29. Gopal, E.; Miyauchi, S.; Martin, P.M.; Ananth, S.; Roon, P.; Smith, S.B.; Ganapathy, V. Transport of Nicotinate and Structurally Related Compounds by Human SMCT1 (SLC5A8) and Its Relevance to Drug Transport in the Mammalian Intestinal Tract. *Pharm. Res.* **2007**, *24*, 575–584. [[CrossRef](#)] [[PubMed](#)]
30. Thangaraju, M.; Gopal, E.; Martin, P.M.; Ananth, S.; Smith, S.B.; Prasad, P.D.; Sterneck, E.; Ganapathy, V. SLC5A8 Triggers Tumor Cell Apoptosis through Pyruvate-Dependent Inhibition of Histone Deacetylases. *Cancer Res.* **2006**, *66*, 11560–11564. [[CrossRef](#)]
31. Martin, P.M.; Gopal, E.; Ananth, S.; Zhuang, L.; Itagaki, S.; Prasad, B.M.; Smith, S.B.; Prasad, P.D.; Ganapathy, V. Identity of SMCT1 (SLC5A8) as a Neuron-Specific Na⁺-Coupled Transporter for Active Uptake of L-Lactate and Ketone Bodies in the Brain. *J. Neurochem.* **2006**, *98*, 279–288. [[CrossRef](#)]
32. Coothankandaswamy, V.; Elangovan, S.; Singh, N.; Prasad, P.D.; Thangaraju, M.; Ganapathy, V. The Plasma Membrane Transporter SLC5A8 Suppresses Tumour Progression through Depletion of Survivin without Involving Its Transport Function. *Biochem. J.* **2013**, *450*, 169–178. [[CrossRef](#)]
33. Helm, J.; Coppola, D.; Ganapathy, V.; Lloyd, M.; Centeno, B.A.; Chen, D.-T.; Malafa, M.P.; Park, J.Y. SLC5A8 Nuclear Translocation and Loss of Expression Are Associated with Poor Outcome in Pancreatic Ductal Adenocarcinoma. *Pancreas* **2012**, *41*, 904–909. [[CrossRef](#)]
34. Bhutia, Y.D.; Babu, E.; Ramachandran, S.; Yang, S.; Thangaraju, M.; Ganapathy, V. SLC Transporters as a Novel Class of Tumour Suppressors: Identity, Function and Molecular Mechanisms. *Biochem. J.* **2016**, *473*, 1113–1124. [[CrossRef](#)]
35. Costello, L.C.; Levy, B.A.; Desouki, M.M.; Zou, J.; Bagasra, O.; Johnson, L.A.; Hanna, N.; Franklin, R.B. Decreased Zinc and Downregulation of ZIP3 Zinc Uptake Transporter in the Development of Pancreatic Adenocarcinoma. *Cancer Biol. Ther.* **2011**, *12*, 297–303. [[CrossRef](#)]
36. Xie, J.; Cheng, C.-s.; Zhu, X.Y.; Shen, Y.H.; Song, L.B.; Chen, H.; Chen, Z.; Liu, L.M.; Meng, Z.Q. Magnesium Transporter Protein Solute Carrier Family 41 Member 1 Suppresses Human Pancreatic Ductal Adenocarcinoma through Magnesium-Dependent Akt/mTOR Inhibition and Bax-Associated Mitochondrial Apoptosis. *Aging* **2019**, *11*, 2681–2698. [[CrossRef](#)]
37. Takagishi, T.; Hara, T.; Fukada, T. Recent Advances in the Role of SLC39A/ZIP Zinc Transporters In Vivo. *Int. J. Mol. Sci.* **2017**, *18*, 2708. [[CrossRef](#)]

38. Torre, L.A.; Siegel, R.L.; Ward, E.M.; Jemal, A. Global Cancer Incidence and Mortality Rates and Trends—An Update. *Cancer Epidemiol. Prev. Biomark.* **2016**, *25*, 16–27. [[CrossRef](#)]
39. Hee Choi, Y.; Yu, A.-M. ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. *Curr. Pharm. Des.* **2014**, *20*, 793–807. [[CrossRef](#)]
40. Miki, Y.; Suzuki, T.; Kitada, K.; Yabuki, N.; Shibuya, R.; Moriya, T.; Ishida, T.; Ohuchi, N.; Blumberg, B.; Sasano, H. Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. *Cancer Res.* **2006**, *66*, 535–542. [[CrossRef](#)] [[PubMed](#)]
41. Obaidat, A.; Roth, M.; Hagenbuch, B. The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer. *Annu. Rev. Pharmacol. Toxicol.* **2012**, *52*, 135–151. [[CrossRef](#)] [[PubMed](#)]
42. Arakawa, H.; Nakanishi, T.; Yanagihara, C.; Nishimoto, T.; Wakayama, T.; Mizokami, A.; Namiki, M.; Kawai, K.; Tamai, I. Enhanced Expression of Organic Anion Transporting Polypeptides (OATPs) in Androgen Receptor-Positive Prostate Cancer Cells: Possible Role of OATP1A2 in Adaptive Cell Growth under Androgen-Depleted Conditions. *Biochem. Pharmacol.* **2012**, *84*, 1070–1077. [[CrossRef](#)] [[PubMed](#)]
43. Muto, M.; Onogawa, T.; Suzuki, T.; Ishida, T.; Rikiyama, T.; Katayose, Y.; Ohuchi, N.; Sasano, H.; Abe, T.; Unno, M. Human Liver-Specific Organic Anion Transporter-2 Is a Potent Prognostic Factor for Human Breast Carcinoma. *Cancer Sci.* **2007**, *98*, 1570–1576. [[CrossRef](#)]
44. Kindla, J.; Rau, T.T.; Jung, R.; Fasching, P.A.; Strick, R.; Stoehr, R.; Hartmann, A.; Fromm, M.F.; König, J. Expression and Localization of the Uptake Transporters OATP2B1, OATP3A1 and OATP5A1 in Non-Malignant and Malignant Breast Tissue. *Cancer Biol. Ther.* **2011**, *11*, 584–591. [[CrossRef](#)] [[PubMed](#)]
45. Svoboda, M.; Wlcek, K.; Taferner, B.; Hering, S.; Stieger, B.; Tong, D.; Zeillinger, R.; Thalhammer, T.; Jäger, W. Expression of Organic Anion-Transporting Polypeptides 1B1 and 1B3 in Ovarian Cancer Cells: Relevance for Paclitaxel Transport. *Biomed. Pharmacother.* **2011**, *65*, 417–426. [[CrossRef](#)]
46. Bleasby, K.; Castle, J.; Roberts, C.; Cheng, C.; Bailey, W.; Sina, J.; Kulkarni, A.; Hafey, M.; Evers, R.; Johnson, J. Expression Profiles of 50 Xenobiotic Transporter Genes in Humans and Pre-Clinical Species: A Resource for Investigations into Drug Disposition. *Xenobiotica* **2006**, *36*, 963–988. [[CrossRef](#)] [[PubMed](#)]
47. Kochel, T.J.; Goloubeva, O.G.; Fulton, A.M. Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer. *Breast Cancer* **2016**, *10*, 61–70. [[PubMed](#)]
48. Nozawa, T.; Suzuki, M.; Takahashi, K.; Yabuuchi, H.; Maeda, T.; Tsuji, A.; Tamai, I. Involvement of Estrone-3-Sulfate Transporters in Proliferation of Hormone-Dependent Breast Cancer Cells. *J. Pharmacol. Exp. Ther.* **2004**, *311*, 1032–1037. [[CrossRef](#)]
49. Wlcek, K.; Svoboda, M.; Riha, J.; Zakaria, S.; Olszewski, U.; Dvorak, Z.; Sellner, F.; Ellinger, I.; Jäger, W.; Thalhammer, T. The Analysis of Organic Anion Transporting Polypeptide (OATP) mRNA and Protein Patterns in Primary and Metastatic Liver Cancer. *Cancer Biol. Ther.* **2011**, *11*, 801–811. [[CrossRef](#)]
50. Roth, M.; Obaidat, A.; Hagenbuch, B. OATPs, OATs and OCTs: The Organic Anion and Cation Transporters of the SLCO and SLC22A Gene Superfamilies. *Br. J. Pharmacol.* **2012**, *165*, 1260–1287. [[CrossRef](#)]
51. Banerjee, N.; Allen, C.; Bendayan, R. Differential Role of Organic Anion-Transporting Polypeptides in Estrone-3-Sulphate Uptake by Breast Epithelial Cells and Breast Cancer Cells. *J. Pharmacol. Exp. Ther.* **2012**, *342*, 510–519. [[CrossRef](#)]
52. Kuo, K.-L.; Zhu, H.; McNamara, P.J.; Leggas, M. Localization and Functional Characterization of the Rat Oatp4c1 Transporter in an In Vitro Cell System and Rat Tissues. *PLoS ONE* **2012**, *7*, e39641. [[CrossRef](#)]
53. Okabe, M.; Szakács, G.; Reimers, M.A.; Suzuki, T.; Hall, M.D.; Abe, T.; Weinstein, J.N.; Gottesman, M.M. Profiling SLCO and SLC22 Genes in the NCI-60 Cancer Cell Lines to Identify Drug Uptake Transporters. *Mol. Cancer Ther.* **2008**, *7*, 3081–3091. [[CrossRef](#)]
54. Albers, A.; Bröer, A.; Wagner, C.A.; Setiawan, I.; Lang, P.A.; Kranz, E.U.; Lang, F.; Bröer, S. Na⁺ Transport by the Neural Glutamine Transporter ATA1. *Pflüg. Arch.* **2001**, *443*, 92–101. [[CrossRef](#)] [[PubMed](#)]
55. Kawakami, I.; Yoshino, H.; Fukumoto, W.; Tamai, M.; Okamura, S.; Osako, Y.; Sakaguchi, T.; Inoguchi, S.; Matsushita, R.; Yamada, Y.; et al. Targeting of the Glutamine Transporter SLC1A5 Induces Cellular Senescence in Clear Cell Renal Cell Carcinoma. *Biochem. Biophys. Res. Commun.* **2022**, *611*, 99–106. [[CrossRef](#)] [[PubMed](#)]
56. Kanai, Y. Amino Acid Transporter LAT1 (SLC7A5) as a Molecular Target for Cancer Diagnosis and Therapeutics. *Pharmacol. Ther.* **2022**, *230*, 107964. [[CrossRef](#)] [[PubMed](#)]
57. Bharadwaj, R.; Anonick, M.V.; Jaiswal, S.; Mashayekh, S.; Brown, A.; Wodzanowski, K.A.; Okuda, K.; Silverman, N.; Grimes, C.L. Synthesis and Validation of Click-Modified NOD1/2 Agonists. *Innate Immun.* **2023**, *29*, 186–200. [[CrossRef](#)]
58. Oda, K.; Hosoda, N.; Endo, H.; Saito, K.; Tsujihara, K.; Yamamura, M.; Sakata, T.; Anzai, N.; Wempe, M.F.; Kanai, Y.; et al. L-Type Amino Acid Transporter 1 Inhibitors Inhibit Tumor Cell Growth. *Cancer Sci.* **2010**, *101*, 173–179. [[CrossRef](#)] [[PubMed](#)]
59. Hu, K.; Li, K.; Lv, J.; Feng, J.; Chen, J.; Wu, H.; Cheng, F.; Jiang, W.; Wang, J.; Pei, H.; et al. Suppression of the SLC7A11/Glutathione Axis Causes Synthetic Lethality in KRAS-Mutant Lung Adenocarcinoma. *J. Clin. Investig.* **2020**, *130*, 1752–1766. [[CrossRef](#)]
60. Macias, R.I.R.; Sánchez-Martín, A.; Rodríguez-Macías, G.; Sánchez-Abarca, L.I.; Lozano, E.; Herraiz, E.; Odero, M.D.; Díez-Martín, J.L.; Marin, J.J.G.; Briz, O. Role of Drug Transporters in the Sensitivity of Acute Myeloid Leukemia to Sorafenib. *Oncotarget* **2018**, *9*, 28474–28485. [[CrossRef](#)]

61. Kamo, S.; Nakanishi, T.; Aotani, R.; Nakamura, Y.; Gose, T.; Tamai, I. Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1. *J. Pharm. Sci.* **2017**, *106*, 2483–2490. [\[CrossRef\]](#)
62. Bhutia, Y.D.; Ganapathy, V. Glutamine Transporters in Mammalian Cells and Their Functions in Physiology and Cancer. *Biochim. Biophys. Acta (BBA)-Mol. Cell Res.* **2016**, *1863*, 2531–2539. [\[CrossRef\]](#)
63. Mueckler, M.; Thorens, B. The SLC2 (GLUT) Family of Membrane Transporters. *Mol. Asp. Med.* **2013**, *34*, 121–138. [\[CrossRef\]](#)
64. Ismail, A.; Tanasova, M. Importance of GLUT Transporters in Disease Diagnosis and Treatment. *Int. J. Mol. Sci.* **2022**, *23*, 8698. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Randazzo, O.; Papini, F.; Mantini, G.; Gregori, A.; Parrino, B.; Liu, D.S.K.; Cascioferro, S.; Carbone, D.; Peters, G.J.; Frampton, A.E.; et al. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. *Cancers* **2020**, *12*, 3206. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Gründemann, D.; Gorboulev, V.; Gambaryan, S.; Veyhl, M.; Koepsell, H. Drug Excretion Mediated by a New Prototype of Polyspecific Transporter. *Nature* **1994**, *372*, 549–552. [\[CrossRef\]](#) [\[PubMed\]](#)
67. Kekuda, R.; Prasad, P.D.; Fei, Y.-J.; Torres-Zamorano, V.; Sinha, S.; Yang-Feng, T.L.; Leibach, F.H.; Ganapathy, V. Cloning of the Sodium-Dependent, Broad-Scope, Neutral Amino Acid Transporter Bo from a Human Placental Choriocarcinoma Cell Line. *J. Biol. Chem.* **1996**, *271*, 18657–18661. [\[CrossRef\]](#)
68. Fuchs, B.C.; Bode, B.P. Amino Acid Transporters ASCT2 and LAT1 in Cancer: Partners in Crime? *Semin. Cancer Biol.* **2005**, *15*, 254–266. [\[CrossRef\]](#)
69. Nolin, E.; Gans, S.; Llamas, L.; Bandyopadhyay, S.; Brittain, S.M.; Bernasconi-Elias, P.; Carter, K.P.; Loureiro, J.J.; Thomas, J.R.; Schirle, M.; et al. Discovery of a ZIP7 Inhibitor from a Notch Pathway Screen. *Nat. Chem. Biol.* **2019**, *15*, 179–188. [\[CrossRef\]](#)
70. Hagenbuch, B.; Meier, P.J. Organic Anion Transporting Polypeptides of the OATP/SLC21 Family: Phylogenetic Classification as OATP/SLCO Superfamily, New Nomenclature and Molecular/Functional Properties. *Pflug. Arch.* **2004**, *447*, 653–665. [\[CrossRef\]](#)
71. Ancona, N.; Maglietta, R.; Piepoli, A.; D’Addabbo, A.; Cotugno, R.; Savino, M.; Liuni, S.; Carella, M.; Pesole, G.; Perri, F. On the Statistical Assessment of Classifiers Using DNA Microarray Data. *BMC Bioinform.* **2006**, *7*, 387. [\[CrossRef\]](#)
72. Ma, H.; Wu, Z.; Peng, J.; Li, Y.; Huang, H.; Liao, Y.; Zhou, M.; Sun, L.; Huang, N.; Shi, M.; et al. Inhibition of SLC1A5 Sensitizes Colorectal Cancer to Cetuximab. *Int. J. Cancer* **2018**, *142*, 2578–2588. [\[CrossRef\]](#)
73. Da Silva, T.C.; Polli, J.E.; Swaan, P.W. The Solute Carrier Family 10 (SLC10): Beyond Bile Acid Transport. *Mol. Asp. Med.* **2013**, *34*, 252–269. [\[CrossRef\]](#) [\[PubMed\]](#)
74. Kayabaşı, Y.; Güneş, B.; Erbaş, O. Serotonin Receptors and Depression. *J. Exp. Basic Med. Sci.* **2021**, *2*, 240–246.
75. Hassanein, M.; Hoeksema, M.D.; Shiota, M.; Qian, J.; Harris, B.K.; Chen, H.; Clark, J.E.; Alborn, W.E.; Eisenberg, R.; Massion, P.P. SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival. *Clin. Cancer Res.* **2013**, *19*, 560–570. [\[CrossRef\]](#) [\[PubMed\]](#)
76. Corti, A.; Dominici, S.; Piaggi, S.; Belcastro, E.; Chiu, M.; Taurino, G.; Pacini, S.; Bussolati, O.; Pompella, A. γ -Glutamyltransferase enzyme activity of cancer cells modulates L- γ -glutamyl-p-nitroanilide (GPNA) cytotoxicity. *Sci. Rep.* **2019**, *9*, 891. [\[CrossRef\]](#) [\[PubMed\]](#)
77. Nakanishi, T.; Tamai, I. Solute Carrier Transporters as Targets for Drug Delivery and Pharmacological Intervention for Chemotherapy. *J. Pharm. Sci.* **2011**, *100*, 3731–3750. [\[CrossRef\]](#) [\[PubMed\]](#)
78. Chu, S.; Zhou, Z.; Karri, S.; Li, Z.; Zhao, J. In Vitro and In Vivo Radiosensitization of Human Glioma U251 Cells Induced by Upregulated Expression of SLC22A18. *Cancer Gene Ther.* **2014**, *21*, 103–109. [\[CrossRef\]](#) [\[PubMed\]](#)
79. Hassanein, M.; Qian, J.; Hoeksema, M.D.; Wang, J.; Jacobovitz, M.; Ji, X.; Harris, F.T.; Harris, B.K.; Boyd, K.L.; Chen, H. Targeting SLC1a5-Mediated Glutamine Dependence in Non-Small Cell Lung Cancer. *Int. J. Cancer* **2015**, *137*, 1587–1597. [\[CrossRef\]](#) [\[PubMed\]](#)
80. Alper, S.L.; Sharma, A.K. The SLC26 Gene Family of Anion Transporters and Channels. *Mol. Asp. Med.* **2013**, *34*, 494–515. [\[CrossRef\]](#)
81. Lu, Y.C.; Yang, J.; Fok, K.L.; Ye, Y.H.; Jin, L.; Chen, Z.Y.; Zhang, X.M.; Huang, H.F.; Chan, H.C. Involvement of Cl⁽⁻⁾/HCO₃⁽⁻⁾ Exchanger SLC26A3 and SLC26A6 in Preimplantation Embryo Cleavage. *Sci. Rep.* **2016**, *6*, 28402. [\[CrossRef\]](#)
82. Amann, T.; Maegdefrau, U.; Hartmann, A.; Agaimy, A.; Marienhagen, J.; Weiss, T.S.; Stoeltzing, O.; Warnecke, C.; Schölmerich, J.; Oefner, P.J.; et al. GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis. *Am. J. Pathol.* **2009**, *174*, 1544–1552. [\[CrossRef\]](#)
83. Kim, Y.H.; Jeong, D.C.; Pak, K.; Han, M.E.; Kim, J.Y.; Liangwen, L.; Kim, H.J.; Kim, T.W.; Kim, T.H.; Hyun, D.W.; et al. SLC2A2 (GLUT2) as a Novel Prognostic Factor for Hepatocellular Carcinoma. *Oncotarget* **2017**, *8*, 68381–68392. [\[CrossRef\]](#)
84. Inoue, K.; Fei, Y.J.; Zhuang, L.; Gopal, E.; Miyauchi, S.; Ganapathy, V. Functional Features and Genomic Organization of Mouse NaCT, a Sodium-Coupled Transporter for Tricarboxylic Acid Cycle Intermediates. *Biochem. J.* **2004**, *378*, 949–957. [\[CrossRef\]](#)
85. Pajor, A.M. Sodium-Coupled Dicarboxylate and Citrate Transporters from the SLC13 Family. *Pflug. Arch.* **2014**, *466*, 119–130. [\[CrossRef\]](#)
86. opnMe.com Boehringer Ingelheim (2024): OpnMe—Boehringer Ingelheim Open Innovation Portal. Available online: <https://www.opnme.com/molecules/slc13a5-bi01383298> (accessed on 11 March 2024).
87. Li, Y.; Shao, H.; Da, Z.; Pan, J.; Fu, B. High Expression of SLC38A1 Predicts Poor Prognosis in Patients with De Novo Acute Myeloid Leukemia. *J. Cell. Physiol.* **2019**, *234*, 20322–20328. [\[CrossRef\]](#)

88. Lai, B.; Lai, Y.; Zhang, Y.; Zhou, M.; Sheng, L.; OuYang, G. The Solute Carrier Family 2 Genes Are Potential Prognostic Biomarkers in Acute Myeloid Leukemia. *Technol. Cancer Res. Treat.* **2020**, *19*, 1533033819894308. [\[CrossRef\]](#)
89. Wang, S.-M.; Sun, L.-L.; Zeng, W.-X.; Wu, W.-S.; Zhang, G.-L. Effects of a microRNA Binding Site Polymorphism in SLC19A1 on Methotrexate Concentrations in Chinese Children with Acute Lymphoblastic Leukemia. *Med. Oncol.* **2014**, *31*, 62. [\[CrossRef\]](#)
90. Ni, F.; Yu, W.-M.; Li, Z.; Graham, D.K.; Jin, L.; Kang, S.; Rossi, M.R.; Li, S.; Broxmeyer, H.E.; Qu, C.-K. Critical Role of ASCT2-Mediated Amino Acid Metabolism in Promoting Leukaemia Development and Progression. *Nat. Metab.* **2019**, *1*, 390–403. [\[CrossRef\]](#)
91. Bröer, S.; Palacin, M. The Role of Amino Acid Transporters in Inherited and Acquired Diseases. *Biochem. J.* **2011**, *436*, 193–211. [\[CrossRef\]](#) [\[PubMed\]](#)
92. Bröer, A.; Wagner, C.A.; Lang, F.; Bröer, S. The Heterodimeric Amino Acid Transporter 4F2hc/y+ LAT2 Mediates Arginine Efflux in Exchange with Glutamine. *Biochem. J.* **2000**, *349*, 787–795. [\[CrossRef\]](#) [\[PubMed\]](#)
93. Grzes, K.M.; Swamy, M.; Hukelmann, J.L.; Emslie, E.; Sinclair, L.V.; Cantrell, D.A. Control of Amino Acid Transport Coordinates Metabolic Reprogramming in T-Cell Malignancy. *Leukemia* **2017**, *31*, 2771–2779. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Ji, X.; Yang, X.; Wang, N.; Kang, M.; Wang, Y.; Rong, L.; Fang, Y.; Xue, Y. Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia. *Cell. Physiol. Biochem.* **2018**, *48*, 731–740. [\[CrossRef\]](#)
95. Ikehata, M.; Ueda, K.; Iwakawa, S. Different Involvement of DNA Methylation and Histone Deacetylation in the Expression of Solute-Carrier Transporters in 4 Colon Cancer Cell Lines. *Biol. Pharm. Bull.* **2012**, *35*, 301–307. [\[CrossRef\]](#)
96. Jonker, J.W.; Schinkel, A.H. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3). *J. Pharmacol. Exp. Ther.* **2004**, *308*, 2–9. [\[CrossRef\]](#)
97. Zhang, S.; Lovejoy, K.S.; Shima, J.E.; Lagpacan, L.L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J.W.; Chen, X. Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. *Cancer Res.* **2006**, *66*, 8847–8857. [\[CrossRef\]](#)
98. Hamada, A.; Sissung, T.; Price, D.K.; Danesi, R.; Chau, C.H.; Sharifi, N.; Venzon, D.; Maeda, K.; Nagao, K.; Sparreboom, A. Effect of SLC01B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. *Clin. Cancer Res.* **2008**, *14*, 3312–3318. [\[CrossRef\]](#)
99. Lee, W.; Belkhir, A.; Lockhart, A.C.; Merchant, N.; Glaeser, H.; Harris, E.I.; Washington, M.K.; Brunt, E.M.; Zaika, A.; Kim, R.B. Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. *Cancer Res.* **2008**, *68*, 10315–10323. [\[CrossRef\]](#) [\[PubMed\]](#)
100. Uemura, T.; Stringer, D.E.; Blohm-Mangone, K.A.; Gerner, E.W. Polyamine Transport is Mediated by Both Endocytic and Solute Carrier Transport Mechanisms in the Gastrointestinal Tract. *Am. J. Physiol.-Gastrointest. Liver Physiol.* **2010**, *299*, G517–G522. [\[CrossRef\]](#) [\[PubMed\]](#)
101. Ban, M.J.; Ji, S.H.; Lee, C.-K.; Bae, S.B.; Kim, H.J.; Ahn, T.S.; Lee, M.S.; Baek, M.-J.; Jeong, D. Solute Carrier Organic Anion Transporter Family Member 4A1 (SLCO4A1) as a Prognosis Marker of Colorectal Cancer. *J. Cancer Res. Clin. Oncol.* **2017**, *143*, 1437–1447. [\[CrossRef\]](#)
102. Phua, L.C.; Mal, M.; Koh, P.K.; Cheah, P.Y.; Chan, E.C.Y.; Ho, H.K. Investigating the Role of Nucleoside Transporters in the Resistance of Colorectal Cancer to 5-Fluorouracil Therapy. *Cancer Chemother. Pharmacol.* **2013**, *71*, 817–823. [\[CrossRef\]](#) [\[PubMed\]](#)
103. Kumamoto, K.; Goto, Y.; Sekikawa, K.; Takenoshita, S.; Ishida, N.; Kawakita, M.; Kannagi, R. Increased Expression of UDP-Galactose Transporter Messenger RNA in Human Colon Cancer Tissues and Its Implication in Synthesis of Thomsen-Friedenreich Antigen and Sialyl Lewis A/X Determinants. *Cancer Res.* **2001**, *61*, 4620–4627.
104. Coburn, L.A.; Singh, K.; Asim, M.; Barry, D.P.; Allaman, M.M.; Al-Greene, N.T.; Hardbower, D.M.; Polosukhina, D.; Williams, C.S.; Delgado, A.G. Loss of Solute Carrier Family 7 Member 2 Exacerbates Inflammation-Associated Colon Tumorigenesis. *Oncogene* **2019**, *38*, 1067–1079. [\[CrossRef\]](#) [\[PubMed\]](#)
105. Kikuchi, D.; Saito, M.; Saito, K.; Watanabe, Y.; Matsumoto, Y.; Kanke, Y.; Onozawa, H.; Hayase, S.; Sakamoto, W.; Ishigame, T. Upregulated Solute Carrier Family 37 Member 1 in Colorectal Cancer is Associated with Poor Patient Outcome and Metastasis. *Oncol. Lett.* **2018**, *15*, 2065–2072. [\[CrossRef\]](#) [\[PubMed\]](#)
106. Panda, S.; Banerjee, N.; Chatterjee, S. Solute Carrier Proteins and c-Myc: A Strong Connection in Cancer Progression. *Drug Discov. Today* **2020**, *25*, 891–900. [\[CrossRef\]](#)
107. Neal, R.D.; Sun, F.; Emery, J.D.; Callister, M.E. Lung Cancer. *BMJ* **2019**, *365*, 11725. [\[CrossRef\]](#)
108. Lehrer, S.; Rheinstein, P.H. Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer. *Cancer Genom. Proteom.* **2018**, *15*, 387–393. [\[CrossRef\]](#)
109. Lichten, L.A.; Cousins, R.J. Mammalian Zinc Transporters: Nutritional and Physiologic Regulation. *Annu. Rev. Nutr.* **2009**, *29*, 153–176. [\[CrossRef\]](#)
110. Zhou, H.; Zhu, Y.; Qi, H.; Liang, L.; Wu, H.; Yuan, J.; Hu, Q. Evaluation of the Prognostic Values of Solute Carrier (SLC) Family 39 Genes for Patients with Lung Adenocarcinoma. *Aging* **2021**, *13*, 5312–5331. [\[CrossRef\]](#)
111. Nair, S.; Strohecker, A.M.; Persaud, A.K.; Bissa, B.; Muruganandan, S.; McElroy, C.; Pathak, R.; Williams, M.; Raj, R.; Kaddoumi, A. Adult Stem Cell Deficits Drive Slc29a3 Disorders in Mice. *Nat. Commun.* **2019**, *10*, 2943. [\[CrossRef\]](#)
112. Chen, X.; Zhang, L.; Ren, S.; Li, X.; Zhou, F.; Li, W.; Gao, G.; He, Y.; Zhou, C. Genomic Polymorphisms of SLC29A3 Associated with Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Gemcitabine. *Med. Oncol.* **2014**, *31*, 865. [\[CrossRef\]](#)
113. Lemstrová, R.; Souček, P.; Melichar, B.; Mohelnikova-Duchonova, B. Role of Solute Carrier Transporters in Pancreatic Cancer: A Review. *Pharmacogenomics* **2014**, *15*, 1133–1145. [\[CrossRef\]](#) [\[PubMed\]](#)

114. Zhu, Q.; Liang, X.; Dai, J.; Guan, X. Prostaglandin Transporter, SLCO2A1, Mediates the Invasion and Apoptosis of Lung Cancer Cells Via PI3K/AKT/mTOR Pathway. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 9175–9181. [[PubMed](#)]
115. Nakata, R.; Nakamura, Y.; Hosomi, S.; Okuda, H.; Nishida, Y.; Sugita, N.; Itani, S.; Nadatani, Y.; Otani, K.; Tanaka, F. Slco 2 a1 Deficiency Exacerbates Experimental Colitis Via Inflammasome Activation in Macrophages: A Possible Mechanism of Chronic Enteropathy Associated with SLCO2A1 gene. *Sci. Rep.* **2020**, *10*, 4883. [[CrossRef](#)] [[PubMed](#)]
116. Wang, Y.; Fu, L.; Cui, M.; Wang, Y.; Xu, Y.; Li, M.; Mi, J. Amino Acid Transporter SLC38A3 Promotes Metastasis of Non-Small Cell Lung Cancer Cells by Activating PDK1. *Cancer Lett.* **2017**, *393*, 8–15. [[CrossRef](#)]
117. Oguri, T.; Kunii, E.; Fukuda, S.; Sone, K.; Uemura, T.; Takakuwa, O.; Kanemitsu, Y.; Ohkubo, H.; Takemura, M.; Maeno, K. Organic Cation Transporter 6 Directly Confers Resistance to Anticancer Platinum Drugs. *Biomed. Rep.* **2016**, *5*, 639–643. [[CrossRef](#)] [[PubMed](#)]
118. Kunii, E.; Oguri, T.; Kasai, D.; Ozasa, H.; Uemura, T.; Takakuwa, O.; Ohkubo, H.; Takemura, M.; Maeno, K.; Niimi, A. Organic Cation Transporter OCT6 Mediates Cisplatin Uptake and Resistance to Cisplatin in Lung Cancer. *Cancer Chemother. Pharmacol.* **2015**, *75*, 985–991. [[CrossRef](#)] [[PubMed](#)]
119. He, H.; Xu, C.; Zhao, Z.; Qin, X.; Xu, H.; Zhang, H. Low Expression of SLC22A18 Predicts Poor Survival Outcome in Patients with Breast Cancer after Surgery. *Cancer Epidemiol.* **2011**, *35*, 279–285. [[CrossRef](#)] [[PubMed](#)]
120. Villanueva, A. Hepatocellular Carcinoma. *N. Engl. J. Med.* **2019**, *380*, 1450–1462. [[CrossRef](#)] [[PubMed](#)]
121. Sia, D.; Villanueva, A.; Friedman, S.L.; Llovet, J.M. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. *Gastroenterology* **2017**, *152*, 745–761. [[CrossRef](#)]
122. Idilman, R.; De Maria, N.; Colantoni, A.; Van Thiel, D.H. Pathogenesis of Hepatitis B and C-Induced Hepatocellular Carcinoma. *J. Viral Hepat.* **1998**, *5*, 285–299. [[CrossRef](#)]
123. Kanwal, F.; Kramer, J.R.; Duan, Z.; Yu, X.; White, D.; El-Serag, H.B. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. *Clin. Gastroenterol. Hepatol.* **2016**, *14*, 301–308.e2. [[CrossRef](#)]
124. Morgan, T.R.; Mandayam, S.; Jamal, M.M. Alcohol and Hepatocellular Carcinoma. *Gastroenterology* **2004**, *127*, S87–S96. [[CrossRef](#)]
125. Wan, Z.; Wang, X. Role of SLC39A6 in the Development and Progression of Liver Cancer. *Oncol. Lett.* **2022**, *23*, 77. [[CrossRef](#)]
126. Cao, J.; Wang, P.; Chen, J.; He, X. Systemic Characterization of the SLC Family Genes Reveals SLC26A6 as a Novel Oncogene in Hepatocellular Carcinoma. *Transl. Cancer Res.* **2021**, *10*, 2882–2894. [[CrossRef](#)]
127. Peng, Q.; Hao, L.Y.; Guo, Y.L.; Zhang, Z.Q.; Ji, J.M.; Xue, Y.; Liu, Y.W.; Lu, J.L.; Li, C.G.; Shi, X.L. Solute Carrier Family 2 Members 1 and 2 as Prognostic Biomarkers in Hepatocellular Carcinoma Associated with Immune Infiltration. *World J. Clin. Cases* **2022**, *10*, 3989–4019. [[CrossRef](#)]
128. Chen, Y.; Zhang, J.; Liu, M.; Zou, Z.; Wang, F.; Hu, H.; Sun, B.; Zhang, S. Risk of Developing Hepatocellular Carcinoma following Depressive Disorder Based on the Expression Level of Oatp2a1 and Oatp2b1. *Biomed. Res. Int.* **2019**, *2019*, 3617129. [[CrossRef](#)]
129. Wu, X.; Gong, C.; Weinstock, J.; Cheng, J.; Hu, S.; Venners, S.A.; Hsu, Y.H.; Wu, S.; Zha, X.; Jiang, S.; et al. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. *Clin. Appl. Thromb. Hemost.* **2018**, *24*, 240s–247s. [[CrossRef](#)] [[PubMed](#)]
130. Bharadwaj, R.; Lusi, C.F.; Mashayekh, S.; Nagar, A.; Subbarao, M.; Kane, G.I.; Wodzanowski, K.A.; Brown, A.R.; Okuda, K.; Monahan, A.; et al. Methotrexate Suppresses Psoriatic Skin Inflammation by Inhibiting Muropeptide Transporter SLC46A2 Activity. *Immunity* **2023**, *56*, 998–1012.e8. [[CrossRef](#)] [[PubMed](#)]
131. Lin, L.; Yee, S.W.; Kim, R.B.; Giacomini, K.M. SLC transporters as Therapeutic Targets: Emerging Opportunities. *Nat. Rev. Drug Discov.* **2015**, *14*, 543–560. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.